Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Prostatic Neoplasms 25Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Breast Neoplasms 13Colonic Neoplasms 9Uterine Cervical Neoplasms 7Lung Neoplasms 6Colorectal Neoplasms 6Urinary Bladder Neoplasms 5Melanoma 5Leukemia, Myeloid, Acute 5Carcinoma, Renal Cell 5Uterine Cervical Dysplasia 4Lymphoma, Large B-Cell, Diffuse 4Esophageal Neoplasms 4Brain Neoplasms 4Thrombocythemia, Essential 3Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Polycythemia Vera 3Papillomavirus Infections 3Oropharyngeal Neoplasms 3Neuroblastoma 3Mouth Neoplasms 3Liver Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Glioma 3Gallbladder Neoplasms 3Carcinoma, Hepatocellular 3

Interventions

Lenalidomide 17Dexamethasone 15Calcium Dobesilate 8daratumumab 5dexamethasone acetate 4dexamethasone 21-phosphate 4carfilzomib 4auricularum 4Melphalan 4Leflunomide 3Curcumin 3isatuximab 2iberdomide 2elotuzumab 2Peripheral Blood Stem Cell Transplantation 2PVX-410 vaccine 2Denosumab 2Cyclophosphamide 2Bortezomib 2siltuximab 1selinexor 1sargramostim 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Watchful Waiting × Clear all
NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
226 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡